By NewsDesk @infectiousdiseasenews
The first 28,800 doses of the COVID-19 vaccine from Oxford University / AstraZeneca were delivered tonight to BulBio’s warehouse. “This is the third type of vaccine and the second in terms of antibody production. It is adenoviral. It is very easy to store and use “, explained the President of the National Vaccination Headquarters Prof. Krassimir Gigov.
When asked by a journalist about the use of the vaccine at Oxford University / AstraZeneca in people over the age of 55, the executive director of the Executive Agency for Medicines, Mag. headlight. Bogdan Kirilov replied that there are still discussions on this topic throughout the European Union. “We are in constant contact with other colleagues. There will be clearer guidelines next week, as we are analyzing the information not only from the EU, but also from the UK, where vaccination with it started earlier. The Committee on Vaccination and Immunization of the United Kingdom also recommends the vaccine for people over 65. In the coming days, there will be instructions from us, as we want to have a picture of all countries where it is used.
The interval between the two doses of the Oxford University / AstraZeneca vaccine is between 4 and 12 weeks. Therefore, the vaccination headquarters is considering using the resulting amount only as a first dose. The final decision will be made next week at a staff meeting.
By the end of February, our country expects four more deliveries of the vaccine from Oxford University / AstraZeneca. 17,550 doses of the Pfizer / BioNTech vaccine will be delivered to Bulgaria on Monday. In the middle of the week we will also receive 6,000 doses of Moderna vaccine.
Europe authorizes AstraZeneca’s COVID-19 vaccine, 3rd vaccine to be approved
Philippines FDA grants EUA to AstraZeneca’s Covid-19 vaccine
Promising results from FIRST COVID-19 pill vaccine tested in humans
Seasonal flu shot reduces COVID-19 symptoms in children: Study
